[Olmesartan and enteropathy a decade later: a perhaps not so exceptional association]. / Olmesartán y enteropatía una década después: una asociación quizá no tan excepcional.
Hipertens Riesgo Vasc
; 39(3): 128-134, 2022.
Article
en Es
| MEDLINE
| ID: mdl-35058164
Olmesartan is a potent angiotensin II receptor antagonist commonly used in the treatment of high blood pressure. During the last decade, several cases of sprue-like enteropathy have been described associated with the use of this drug - with severe clinical involvement that requires hospitalization - but fortunately with complete remission after its discontinuation. We present the case of a multi-pathological 82-year-old woman with a chronic diarrhoeal syndrome that resulted in a weight loss of 20kg over the last three months. She was prescribed dual therapy for her hypertension: olmesartan 40mg, torasemide 10mg, and lercanidipine 10mg/day. Based on the findings of the patient presented, we conducted a literature search of all the cases published in Spanish indexed journals (PubMed) and compared them, attempting to establish a suspicion profile that would result in the suspension of olmesartan and accelerate the complementary tests necessary to rule out other diagnoses.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Enfermedad Celíaca
/
Hipertensión
Tipo de estudio:
Risk_factors_studies
Límite:
Aged80
/
Female
/
Humans
Idioma:
Es
Revista:
Hipertens Riesgo Vasc
Año:
2022
Tipo del documento:
Article
Pais de publicación:
España